Loading
A surface protein found on myeloma cells and on natural killer cells. Elotuzumab tags myeloma cells with it while also switching on the natural killer cells that carry it.
SLAMF7, also known as CS1 or CD319, is a signalling lymphocyte activation molecule family receptor expressed at high levels on malignant plasma cells and on natural killer cells, with little expression on other normal tissues. Elotuzumab, a humanised antibody against SLAMF7, marks myeloma cells for antibody-dependent cellular cytotoxicity and directly activates natural killer cells through the same receptor. It has no single-agent activity but improves outcomes with lenalidomide or pomalidomide plus dexamethasone, the basis of its 2015 and 2018 approvals.
In plain words · A surface protein found on myeloma cells and on natural killer cells. Elotuzumab tags myeloma cells with it while also switching on the natural killer cells that carry it.
A surface protein found on myeloma cells and on natural killer cells. Elotuzumab tags myeloma cells with it while also switching on the natural killer cells that carry it.
SLAM family receptor signalling through EAT-2 in natural killer cells; highly expressed on plasma cells and myeloma cells.
No product in this corpus aims at SLAMF7 (CS1) yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Tumour-associated overexpression: 1 antibody (Elotuzumab) aim at the antigen, which HPA finds stained high in 2 normal tissues; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA SLAMF7: RNA tissue enhanced (intestine 31 nTPM, lymphoid tissue 58 nTPM, stomach 1 32 nTPM); high antibody staining in 2 normal tissues. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Multiple myeloma); Open Targets associates it with 1 specific cancer type at or above 0.5 (plasma cell myeloma). (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas SLAMF7 tissue; Human Protein Atlas SLAMF7 pathology; Open Targets ENSG00000026751 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Fujii et al, 1999, "Homo sapiens mRNA for FOAP-12 protein, complete cds". Source.
SLAM family receptor signalling through EAT-2 in natural killer cells; highly expressed on plasma cells and myeloma cells.
RNA: tissue enhanced (intestine 31 nTPM, lymphoid tissue 58 nTPM, stomach 1 32 nTPM), detected in many normal tissues.
Medium: Appendix, Bone marrow, Lymph node, Spleen, Testis, Tonsil.
RNA cancer enhanced: Testicular Germ Cell Tumor 44 pTPM.
No cancer stained high; medium in lymphoma.
HPA SLAMF7 tissue · HPA SLAMF7 pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Multiple myeloma | over 95% | CS1 (SLAMF7) expression on myeloma cells | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"SLAMF7" OR ABSTRACT:"SLAMF7" OR TITLE:"CS1" OR ABSTRACT:"CS1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SLAMF7 (CS1), not a curated reading list.
Shares Elotuzumab, Multiple myeloma.
Shares Elotuzumab, Multiple myeloma.
Shares Elotuzumab, Multiple myeloma.
Shares Elotuzumab, Multiple myeloma.
Shares Elotuzumab, Multiple myeloma.
Shares ADCC (antibody-dependent cellular cytotoxicity), Multiple myeloma.